Team assessing if dual-antibody injection prevents COVID-19 illness

October 14, 2020

REGN-COV2 is a combination of two laboratory-made antibodies. Patients will receive four subcutaneous injections of either the trial agent or a placebo. (Photo by: Getty Images)

A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.

The Phase III, randomized, double-blinded, placebo-controlled trial will help researchers determine if the laboratory-made dual-antibody treatment, REGN-COV2, can prevent SARS-CoV-2 infection in individuals who share a home with someone with a confirmed infection.

Read the full story, featuring Dr. Arduino…

September 24, 2020

Share content